The effect of herbal medicine danshensu and ursolic acid on pharmacokinetics of rosuvastatin in rats

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 36, Issue 4, 2011, Pages 205-211

  Wen, Jin Hua ^a   Xiong, Yu Qing ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Danshensu; Herb drug interaction; Rat; Rosuvastatin; Transporters; Ursolic acid

Indexed keywords

3 (3,4 DIHYDROXYPHENYL)LACTIC ACID; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1A2; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3; POLYPEPTIDE; ROSUVASTATIN; TAUROCHOLATE COTRANSPORTING POLYPEPTIDE; UNCLASSIFIED DRUG; URSOLIC ACID;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; HERB DRUG INTERACTION; HERBAL MEDICINE; ISOENZYME ANALYSIS; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CLEARANCE; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; DRUGS, CHINESE HERBAL; FLUOROBENZENES; HERB-DRUG INTERACTIONS; LACTATES; MALE; ORGANIC ANION TRANSPORT POLYPEPTIDE C; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TRITERPENES;

EID: 84856237147     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0048-7     Document Type: Article

References (41)

1. Chan K, Chui SH, Wong DY, Ha WY, Chan CL, Wong RN (2004) Protective effects of danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunction. Life Sci 75:3157-3171 (Pubitemid 39361173)
2. Cheng TO (2006) Danshen: a versatile Chinese herbal drug for the treatment of coronary heart disease. Int J Cardiol 113:437-438 (Pubitemid 44708326)
3. Cheng ZH, Lou YP, Dai HJ, Xue F (1987) Studies on effects of "danshensu" on experimental microcirculatory disturbances and plasma lactic acid concentrations. Shanghai Yike Daxue Xuebao 14:25-29
4. Chunshan G, Amanda O, Rathnam C, Bruno H (2010) Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics 4:1-8
5. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV (2002) The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 58(8):527-531 (Pubitemid 35435506)
6. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV (2003a) Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 73(4):322-329 (Pubitemid 36403592)
7. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW (2003b) Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 155:94-99 (Pubitemid 36110844)
8. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW (2003c) The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 59(1):51-56 (Pubitemid 36702759)
9. Dong ZT, Jiang WD (1982) Effect of danshensu on isolated swine coronary artery perfusion preparation. Yaoxue Xuebao 17:226-228
10. Fan L, Zhang W, Guo D, Tan ZR, Xu P, Li Q, Liu YZ, Zhang L, He TY, Hu DL, Wang D, Zhou HH (2008) The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther 83(3):471-476 (Pubitemid 351272636)
11. Handrean S, Paul DU (2008) Rosuvastatin: efficacy, safety and clinical effectiveness. Pharmacotherapy 9(12):2145-2160
12. Hiromi F, Hiroki S, Masayuki T, Ohdo S, Ohtani H, Sawada Y (2006) Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 34:577-582
13. Izzo AA, Di CG, Borrelli F, Ernst E (2006) Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 7:93-110
14. James MM (2005) Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am Soc Health-Syst Pharm 62:1033-1047
15. Kitamura S, Maeda K, Wang Y, Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014-2023
16. Kumar TR, Shitut NR, Kumar PK, Vinu MC, Kumar VV, Mullangi R, Srinivas NR (2006) Determination of rosuvastatin in rat plasma by HPLC: validation and its application to pharmacokinetic studies. Biomed Chromatogr 20:881-887 (Pubitemid 44430546)
17. Li CZ, Yang SC, Zhao FD, Yang YQ, Yang CX, Zhang DC (1983) Anticoagulant studies of danshen. Zhongxiyi Jiehe Zazhi 3:297-299
18. Liao QF, Yang W, Jia Y, Chen XH, Gao QT, Bi KS (2005) LC-MS determination and pharmacokinetic studies of ursolic acid in rate plasma after administration of the traditional Chinese medicinal preparation Lu-Ying extract. Pharm Soc Jpn 125(6):509-515 (Pubitemid 40874445)
19. Liu XQ, Luo XT, Ouyang XA (2001) Research advance of Fufang Danshen dosage forms. Shizhen Guoyi Guoyao 12:474-475
20. Mc TF, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M (2001) Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87(suppl 5A):28B-32B (Pubitemid 32274242)
21. Nezasa K, Higaki K, Matsumura T, Inazawa K, Hasegawa H, Nakano M, Koike M (2002) Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 30:1158-1163 (Pubitemid 35265820)
22. Nezask K, Higaki K, Takeuchi M, Nakano M, Koike M (2003) Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica 33:379-388 (Pubitemid 36688114)
23. Olsson AG, McTaggart F, Raza A (2002) Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 20:303-328 (Pubitemid 36105783)
24. Pan HY, Zhao XP, Zhou Q (2008) Pharmacokinetics and bioavailability study of danshensu in rat. China J Chin Materia Medica 33(2):146-148
25. Parfente'eva EP (1979) Effect of ursolic acid and its derivatives on lipid metabolism in experimental atherosclerosis. Chem Abstr 19:91-92
26. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726-733 (Pubitemid 350114817)
27. Qiang F, Lee BJ, Lee W, Han HK (2009) Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats. Eur J Pharm Sci 37:413-417
28. Richard HHM, Richard BKM (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260-277
29. Richard HH, Rommel GT, Brenda FL, Hartmut G, Wooin L, Christopher JL, Yi W, Richared BK (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806
30. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75(5):455-463 (Pubitemid 38534566)
31. Somova LO, Nadar A, Rammanan P, Shode FO (2003) Cardiovascular, antihyperlipidemic and antioxidant effects of oleanolic and ursolic acids in experimental hypertension. Phytomedicine 10:115-121 (Pubitemid 36433204)
32. Su XH, Liang DQ, Wang XM (1992) The effect of danshensu (DS-182) of the injury of oxygen free radicals in myocardial mitochondria from rat myocardium. Zhongguo Bingli Shengli Zazhi 8:122-124
33. Sun CM, Cai HJ, Song SY (1991) New pharmacology effect of Danshensu. Zhong Chao Yao 21(1):20
34. Tang LH, Wang XM, Liang DQ (1989) The protection of DS-182 during reperfusion of total ischemia heart. Zhongguo Bingli Shengli Zazhi 5:65-69
35. Vasilenko YK, Lisevitskaya LI, Frolova LM, Parfenteva EP, Ske IV, Vasilenko AY, Kozharskii VV, Voskanyan VL (1982) Hypolipemic properties of triterpenoids. Farmakol Toksikol 45:66-70
36. Wen J, Xiong Y (2010) OATP1B1 388A > G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J Clin Pharm Ther 35:99-104
37. White CM (2002) A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 42:963-970 (Pubitemid 34920793)
38. Xiong B (2004) Research advance of ursolic acid pharmacology. Foreign Med Sci, Sect Pharm 31:133-135
39. Zhao FQ, Wang AL, Wang L (1994) The distribution studies of Danshensu in rabbit body. J Chin Pharm 29(5):2911
40. Zhao BL, Zhao Y, Jiang W, Hou JW, Xin WJ (1996) Scavenging effects of Salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. Biochem Mol Biol Int 8:1171-1182 (Pubitemid 26334731)
41. Zhou L, Zuo Z, Chow MSS (2005) Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45:1345-1359 (Pubitemid 41643896)